Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.64 |
| ▸ | DPP9 | Q86TI2 | 14/20 | 0.61 |
| ▸ | DPP8 | Q6V1X1 | 13/20 | 0.61 |
| ▸ | FAP | Q12884 | 11/20 | 0.61 |
| ▸ | DPP7 | Q9UHL4 | 11/20 | 0.61 |
| ▸ | PITRM1 | Q5JRX3 | 5/20 | 0.53 |
| ▸ | PREP | P48147 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13417319 | 1.00 | DPP4 (0.64) | DPP4DPP9DPP8FAPDPP7 | |
| SCHEMBL8288237 | 1.00 | DPP4 (0.64) | DPP4DPP9DPP8FAPDPP7 | |
| SCHEMBL13417322 | 1.00 | DPP4 (0.64) | DPP4DPP9DPP8FAPDPP7 | |
| SCHEMBL13347232 | 1.00 | DPP4 (0.64) | DPP4DPP9DPP8FAPDPP7 | |
| SCHEMBL13347234 | 1.00 | DPP4 (0.64) | DPP4DPP9DPP8FAPDPP7 | |
| SCHEMBL13417269 | 0.84 | DPP4 (0.66) | DPP4DPP9DPP8FAPDPP7 | |
| SCHEMBL13347200 | 0.84 | DPP4 (0.66) | DPP4DPP9DPP8FAPDPP7 | |
| SCHEMBL8287929 | 0.84 | DPP4 (0.66) | DPP4DPP9DPP8FAPDPP7 | |
| SCHEMBL13034870 | 0.83 | DPP4 (0.64) | DPP4DPP9DPP8FAPDPP7 | |
| SCHEMBL24322709 | 0.76 | DPP4 (1.00) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120661-A1 | HETEROCYCLIC BORONIC ACID COMPOUNDS | PHENOMIX CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-7674913-B2 | Heterocyclic boronic acid compounds | PHENOMIX CORPORATION (US) | 2010-03-09 | — | — | US | disclosed |
| EP-1997533-A1 | Heterocyclic boronic acid compounds, dipeptidyl peptidase IV inhibitors | Phenomix Corporation (US) | 2008-12-03 | — | — | EP | disclosed |
| WO-2005047297-A1 | HETEROCYCLIC BORONIC ACID COMPOUNDS | PHENOMIX CORPORATION (US) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120661-A1 | HETEROCYCLIC BORONIC ACID COMPOUNDS | DPP4, DPP7, DPP3 | DPP4 1/4885DPP9 7/4885DPP8 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.